CanCOG®: Pilot Trial of Cognitive Rehabilitation for Cancer Survivors
NCT07755839, Not applicable, Not yet recruiting, Aveiro University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | CanCOG®: Pilot Trial of Cognitive Rehabilitation for Cancer Survivors | ClinicalTrials.gov |
| NCT number | NCT07755839 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Aveiro University | ClinicalTrials.gov |
| Conditions | Cancer-related Cognitive Impairment, Cancer-related Cognitive Dysfunction, Cancer-related Cognitive Difficulties, Depression and Anxiety Symptoms, Quality of Life | ClinicalTrials.gov |
| Interventions | CanCOG® - Cogntive Rehabilitation in Cancer | ClinicalTrials.gov |
| First posted | 2026-08-10 | ClinicalTrials.gov |
| Last updated | 2026-08-10 | ClinicalTrials.gov |
Registered outcomes 21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Feasibility - Screening rate | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups. | Screening rate will be assessed as the proportion of potentially eligible cancer survivors who undergo eligibility screening. | ClinicalTrials.gov |
| Primary | Feasibility - Eligibility rate | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups | The eligibility rate will be assessed as the proportion of screened individuals who meet the eligibility criteria. Reasons for ineligibility will be documented whenever available. | ClinicalTrials.gov |
| Primary | Feasibility - Consent rate | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups. | Consent rate will be assessed as the proportion of eligible individuals who provide informed consent. Reasons for refusal to participate will be documented whenever available. | ClinicalTrials.gov |
| Primary | Feasibility - Retention rate | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups | Retention rate will be assessed as the proportion of participants who remain enrolled until study completion. Reasons for withdrawal will be documented whenever available. | ClinicalTrials.gov |
| Primary | Feasibility - Assesment completion rate | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups | Assessment completion rate will be assessed as the proportion of participants completing assessments at each assessment time point. Reasons for missed assessments will be documented whenever available. | ClinicalTrials.gov |
| Primary | Feasibility - Intervention adherence | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups | Intervention adherence will be assessed as the proportion of intervention sessions attended by participants allocated to the intervention group. Reasons for missed sessions will be documented whenever available. | ClinicalTrials.gov |
| Primary | Feasibility - Intervention fidelity | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups | Intervention fidelity, the extent to which the intervention is delivered according to the intervention manual and session plans, will be assessed through facilitator-completed fidelity checklists. | ClinicalTrials.gov |
| Primary | Acceptability - Participant retention and intervention adherence | Baseline ( 2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up. | Acceptability of the intervention will be assessed using participant retention (proportion of participants who remain enrolled until study completion) and intervention adherence (proportion of intervention sessions attended by participants allocated to the intervention group). | ClinicalTrials.gov |
| Primary | Acceptability - Qualitative feedback | Post-intervention (2 weeks after) | Acceptability will be assessed through semi-structured interviews conducted with 10-15 participants from the intervention group. Interviews will explore participants' perceptions of the intervention content, format, duration, group delivery, perceived usefulness, and barriers or facilitators to participation. | ClinicalTrials.gov |
| Primary | Acceptability - ACRIS-CS | Baseline (2 weeks before intervention) and post-intervention (2 weeks after). | Acceptability will also be assessed through the Acceptability of Cognitive Rehabilitation Interventions Survey-Cancer Survivors (ACRIS-CS). This 11-item instrument evaluates participants' perceptions of the intervention's acceptability, including its perceived usefulness, appropriateness, and overall satisfaction. Higher scores indicate greater acceptability of the cognitive rehabilitation intervention. | ClinicalTrials.gov |
| Secondary | Perceived cognitive functioning | Baseline (2 weeks before intervention), post-intervention (2weeks after), 3-month and 6-month follow-ups. | Perceived cognitive functioning will be assessed with the Functional Assessment of Cancer Therapy-Cognitive Function version 3 (FACT-Cog v3). It consists of a 37-item self-report questionnaire composed of four subscales: Perceived Cognitive Impairments (CogPCI), Perceived Cognitive Abilities (CogPCA), Comments from Others (CogOth), and Impact on Quality of Life (CogQoL). The higher the score, the better the perceived functioning. | ClinicalTrials.gov |
| Secondary | Objective cognitive functioning (Global cognition) | Baseline (2 weeks before intervention), Post-intervention (2 weeks after), and 3-month and 6-month follow-up. | Global cognition will be assessed using the Montreal Cognitive Assessment (MoCA). The instrument's scores range from 0 to 30, with lower scores indicating poorer cognitive performance. | ClinicalTrials.gov |
| Secondary | Objective cognitive functioning (Verbal learning and memory) | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up. | The test includes immediate recall across five learning trials, delayed recall after 30 minutes, and a recognition trial, allowing the assessment of acquisition, retention, and recognition processes. Lower scores indicate poorer performance. | ClinicalTrials.gov |
| Secondary | Objective cognitive functioning (Attention and processing speed) | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up. | Attention and processing speed will be assessed with the Trail Making Test Part A (TMT-A) and D2 Test of Attention. TMT- A: Performance is based on completion time and errors. Higher adjusted scores correspond to better performance. D2 Test of Attention: The scoring of this test provides the following results: Total Characters Processed, Total Correct Responses, Total Efficiency and Concentration Index. Higher scores suggest better performance. | ClinicalTrials.gov |
| Secondary | Objective cognitive functioning (Executive functioning and cognitive flexibility) | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up. | Executive functioning and cognitive flexibility will be assessed using the Trail Making Test Part B (TMT-B). Performance is based on completion time and errors. Higher adjusted scores correspond to better performance. | ClinicalTrials.gov |
| Secondary | Objective cognitive functioning (Working memory) | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up. | Working memory will be assessed using the Wechsler Adult Intelligence Scale's (WAIS) - Digit Span subtest. It consists of three components: Digit Span forward, Digit Span Backward, and Digit Span sequencing. Higher scores indicate better performance. | ClinicalTrials.gov |
| Secondary | Objective cognitive functioning (Verbal fluency) | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up. | Verbal fluency will be assessed with the Verbal Fluency Test (VFT). For the VFT, participants are required to remember, in one minute, the maximum number of words possible started by a specific letter or belonging to a specific category. A higher number of words recalled indicates better cognitive performance. | ClinicalTrials.gov |
| Secondary | Objective cognitive functioning (Inhibitory control) | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up. | Inhibitory control will be assessed with the Stroop Color and Word Test. It consists of three tasks: reading words, naming colors, and identifying the color in which each word is written, regardless of the word's meaning. The performance is scored as the number of correct responses completed within the specified time for each condition. Higher scores indicate better performance. | ClinicalTrials.gov |
| Secondary | Anxiety Symptoms | Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups. | Anxiety symptoms will be assessed using the Generalized Anxiety Disorder Scale (GAD-7). It consists of seven items evaluating the presence of anxiety-related symptoms. Scores range from zero to 21, with higher scores indicating greater anxiety severity. | ClinicalTrials.gov |
| Secondary | Depressive Symptoms | Baseline (2 weeks before intervention) , post-intervention (2 weeks after), and 3-month and 6-month follow-up. | Depressive symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9), a 9-item self-report measure of depression severity based on DSM criteria. Total scores range from 0 to 27, with higher scores indicate more severe depressive symptoms. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 33
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 20957426 | BACKGROUND | PubMed |
| 22082082 | BACKGROUND | PubMed |
| 22918524 | BACKGROUND | PubMed |
| 23299183 | BACKGROUND | PubMed |
| 23955490 | BACKGROUND | PubMed |
| 24012579 | BACKGROUND | PubMed |
| 25580839 | BACKGROUND | PubMed |
| 25759235 | BACKGROUND | PubMed |
| 25908249 | BACKGROUND | PubMed |
| 26978655 | BACKGROUND | PubMed |
| 29345974 | BACKGROUND | PubMed |
| 29403314 | BACKGROUND | PubMed |
| 31147780 | BACKGROUND | PubMed |
| 31617564 | BACKGROUND | PubMed |
| 31959511 | BACKGROUND | PubMed |
| 32996583 | BACKGROUND | PubMed |
| 34498828 | BACKGROUND | PubMed |
| 34812790 | BACKGROUND | PubMed |
| 34830829 | BACKGROUND | PubMed |
| 36240847 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Cancellation Test | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)